@FierceMedDev: NIH launches study of 'exceptional responders' to cancer therapies. Article | Follow @FierceMedDev
@MichaelGFierce: Purdue team recreates tumor microenvironment to study cancer nanomed delivery. FierceDrugDelivery story | Follow @MichaelGFierce
@VarunSaxena2: Titan Pharma trial of implant for addicts on track. FierceDrugDelivery story | Follow @VarunSaxena2
@EmilyWFierce: 3-D printed blood vessels? Check. On to the 3-D printed kidneys, say researchers at Harvard. More from MIT Technology Review | Follow @EmilyWFierce
> Medtronic ($MDT) plans to launch a smartphone-enabled continuous glucose monitor, the medical device giant said at the Health 2.0 conference in Santa Clara, CA, this week. It plans to start a pivotal clinical trial of the system this fall. Story
> Zyga Technology raised $10 million to start marketing and further study its minimally invasive spinal surgery products. Of this, Silicon Valley Bank is providing $8 million in debt, while existing investors including Versant Ventures, Split Rock Partners, Domain Associates and MB Venture Partners are offering $2 million in equity. Release
> Liver disease device company Vital Therapies has filed to raise up to $46 million in a follow-on offering. It expects to use the funds to get Phase III data for its ELAD System, an external, allogeneic cellular therapy device that incorporates human liver-derived cells. Filing
> Wireless continuous glucose monitoring company Echo Therapeutics ($ECTE) will suspend operations because it was unable to raise financing. Release
Biotech News
@FierceBiotech: VentiRx banks $50M as it ramps up immuno-oncology research efforts in Seattle. Report | Follow @FierceBiotech
@JohnCFierce: Adaptimmune gathers $104M to fuel hot immuno-oncology tech race - TCRs/CAR-T. More | Follow @JohnCFierce
@DamianFierce: Here's the official Kadmon release on the Waksal swap, replete with semi-acknowledgement of IPO plot. Release | Follow @DamianFierce
@EmilyMFierce: This @BW on Ebola misses the mark in so many ways and lacks a basic understanding of drug development. Article | Follow @EmilyMFierce
> Alzheimer's biotech Probiodrug plots a Euro IPO amid a continental boomlet. News
> Valeant talks up the billion-dollar potential of its Phase III eye drug. Story
> Novartis' blockbuster hopeful scores a win in psoriatic arthritis. Article
Pharma News
@FiercePharma: ICYMI yesterday: Overseas limits on J&J's Olysio use might signal trouble back home. Item | More | Follow @FiercePharma
@EricPFierce: Mylan proposes plan to avoid nitroglycerin shortage in Canada. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce
> Pfizer preps its case for FDA pulling Chantix's black-box warning. Article
> Hail GSK's chairman-to-be Philip Hampton: It's a tough job ahead. Item
> Hey, Big Pharma: When the feds swoop in, be nice. It worked for Shire. More
Vaccines News
> Inovio joins Ebola fight while WHO says a vaccine could be ready by year's end. Story
> CureVac inks lung cancer vaccine deal with Boehringer for up to $600M. Report
> U.K. panel under pressure to extend use of Merck's Gardasil to boys. Article
> Pharmacies continue push to lower barriers to seasonal flu vaccination. Report
> Accidental poliovirus dump adds to GSK's production woes. More
Pharma Manufacturing News
> IGI jumps into sterile injectable biz with $9.5M deal with AstraZeneca. More
> Report: 'Green' manufacturing needed to save money as well as the environment. Item
> Sanofi expands production at Merial plant in Brazil. More
> Alkermes manufacturing technology key to Acorda buyout of Civitas. Article
> Impax settles securities suit tied to its manufacturing issues. Story